Healthcare / BiotechnologyNasdaqGS
$3.38
+0.05 (+1.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-49.6M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-159.8%
↓Gross Margin
N/A
•Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-55.8M · FCF $-49.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | — | — | — | — | — | — | $22.4M | $6.3M | — |
| Net Income | $-55.8M | $-55.8M | $-55.7M | $-62.7M | $-74.7M | $-69.4M | $-36.6M | $-33.7M | $-22.8M |
| EBITDA | $-55.4M | $-55.4M | $-54.3M | $-64.0M | $-71.8M | $-66.5M | $-37.8M | $-34.8M | $-21.5M |
| EPS | -19.65 | -19.65 | -23.88 | -27.00 | -32.28 | -30.12 | -15.96 | — | — |
| Operating Margin | — | — | — | — | — | — | -184.2% | -590.5% | — |
| Net Margin | — | — | — | — | — | — | -163.6% | -531.5% | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.15 | 0.15 | 0.09 | 0.06 | 0.04 | 0.00 | 0.01 | 0.01 | -0.00 |
| Current Ratio | 4.61 | 4.61 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-49.6M | $-49.6M | $-41.3M | $-53.8M | $-56.0M | $-59.6M | $-52.1M | $-39.0M | $4.9M |
| Returns | |||||||||
| ROE | -159.8% | -159.8% | -85.0% | -54.8% | -44.6% | -29.7% | -12.5% | -10.5% | 48.6% |
| Valuation | |||||||||
| P/B | 0.28 | 0.28 | 0.35 | 0.29 | 0.27 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | — | — | — | — | — | — | 252.6% | — | — |
| EPS Growth | 17.7% | 17.7% | 11.6% | 16.4% | — | -88.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-23.88 → -19.65
Residual
-40.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.